Sildenafil Citrate Tablet, Film Coated
Product Images NDC 68071-3862

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 68071-3862). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 3862 9)

Pdp (68071 3862 9)
Sildenafil 100 mg tablets label from NuCare Pharmaceuticals, Inc. The film-coated oral tablets are blue, round biconvex, debossed with '88' on one side. The package contains 90 tablets. Includes NDC 68071-3862-9 and product number P2189090. The label states Rx Only and storage instructions at controlled temperature 68-77°F.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure diagram of the active ingredient Sildenafil, showing its molecular arrangement including rings, nitrogen, oxygen, sulfur atoms, and a citrate component.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph depicting changes in systolic blood pressure (mmHg) over time (hours) post-dose for Sildenafil 100 mg and placebo. The x-axis shows time post dose from pre-dose to 24 hours, and the y-axis shows systolic blood pressure changes ranging approximately from -25 to 15 mmHg. Two lines represent measurements for Sildenafil 100 mg (circles) and placebo (diamonds).*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing change in systolic blood pressure (SBP) over time in hours postdose. It compares two groups: Doxazosin with Placebo and Doxazosin with Sildenafil 25 mg. The y-axis represents change in SBP in mmHG, and the x-axis shows time postdose from 0 to 8 hours. The graph shows trends in SBP changes for the two treatment groups over the 8-hour period.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph showing the change in systolic blood pressure (SBP) in mmHg over 8 hours postdose. Two treatments are compared: Doxazosin plus Placebo (gray line) and Doxazosin plus Sildenafil 50 mg (black line). The black line shows a greater initial decrease in SBP compared to the gray line, with changes plotted at multiple time points from 0 to 8 hours postdose.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing blood pressure changes (mmHg) over time (0 to 8 hours) after dosing with Doxazosin combined with Sildenafil 100 mg versus Doxazosin with placebo. The graph plots the time after dosing on the x-axis and mmHg on the y-axis, comparing the two treatments' effects on blood pressure over the 8-hour period.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A pharmacokinetic line graph showing plasma concentrations (ng/ml) of a commercial sildenafil tablet over time post dose (hours). The graph illustrates concentration peaks sharply before declining steadily over 24 hours, with data points marked by circles representing the commercial tablet treatment.*
FDA Label Image

Figure-6-1 (Figure 6 1)

Figure-6-1 (Figure 6 1)
A bar chart depicting the percentage of patients at endpoint across different baseline score categories (0 through 5). Each baseline score group shows multiple bars representing different patient percentages, with a legend indicating categories labeled 0 to 5. The y-axis shows percentage values up to 80%.*
FDA Label Image

Figure-6-2 (Figure 6 2)

Figure-6-2 (Figure 6 2)
A bar chart depicting the percentage of patients at endpoint categorized by their baseline score. The horizontal axis shows baseline scores from 0 to 5, while the vertical axis indicates the percentage of patients. Different shaded bars represent various patient groups or conditions, as defined in the legend on the right side of the chart.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
A bar chart illustrating the percentage of patients reporting improvement across four groups: placebo (24%, n=463), sildenafil citrate 25 mg (63%, n=214), 50 mg (74%, n=391), and 100 mg (82%, n=380). The y-axis represents percentage improvement, ranging from 0 to 100%.*
FDA Label Image

Image Description (Torrent Logo Copy)

Image Description (Torrent Logo Copy)
FDA Label Image
Image Description (Torrent Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.